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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects and harms of interventions for the maintenance of surgically-induced remission in Crohn’s disease and to rank
treatments in order of effectiveness.
B A C K G R O U N D
Description of the condition
Crohn’s disease is a chronic inflammatory disorder that can involve
any part of the gastrointestinal tract. There is no cure for the
disease, somanagement strategies are instead focused on induction
and maintenance of remission, as well as supporting the many
other symptoms that impact patients affected by the condition.
Approximately 75% of patients with Crohn’s disease will eventu-
ally undergo surgical resection (Bernell 2000), with recent stud-
ies suggesting a rate of 3.8 operations per 100 person years (Ma
2017), and this can induce remission. However endoscopic recur-
rence of disease has been reported to be as high as 73% at one
year post surgery (Rutgeerts 1990), and clinical relapse rates have
been reported to range from 20 to 86% at five years post surgery
( Gklavas 2017; Rutgeerts 2002).
Given these high relapse rates, there have been many studies to
identify potential methods of prolonging postoperative remission,
but there is no standard therapy for the prevention of postoperative
recurrence in Crohn’s disease (Hanuaer 2001; NICE 2016). A
number of agents have been studied, but considerable uncertainty
remains as to the efficacy of such treatments.
Description of the intervention
Corticosteroids, the mainstay of treatment of acute exacerbations,
are not effective for maintenance of remission in Crohn’s disease
(Steinhart 2003), and chronic use is limited by numerous adverse
events.
Probiotics and budesonide do not appear to provide any benefit for
maintenance of surgically-induced remission (Doherty 2009). Ni-
troimidazole antibiotics may reduce relapse after surgery, although
this benefit did not remain significant on sensitivity analysis and
the antibiotics were not well tolerated and associated with a higher
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risk of serious adverse events (Doherty 2009).
5-aminosalicylates are a group of compounds that have long been
used in inflammatory bowel disease. The first 5-aminosalicylate
agent used in clinical practice was sulphasalazine, which is com-
posed of sulphapyridine linked by an azo bond to 5-aminosalicylic
acid (5-ASA). Sulphasalazine was first used in the 1940s as a treat-
ment for arthritis (Svartz 1942). Improvement in gastrointestinal
symptoms was noted in patients who had concurrent ulcerative
colitis leading to further use of this agent in inflammatory bowel
disease. 5-Aminosalicylic acid agents have been shown to be safe
and may be effective for maintenance of post-surgical remission
when compared with placebo (Gordon 2011).
Purine analogues, such as azathioprine and 6-mercaptopurine,
have also been shown to be effective when compared with placebo
(Gordon 2014). However, on review the majority of studies com-
pared these agents with 5-ASA and failed to demonstrate supe-
riority, with more issues leading to withdrawal of therapy noted
(Gordon 2014). These reviews led to the National Institute for
Health and Care Excellence in the UK to change their guidance
for maintenance of post-surgical remission in Crohn’s disease to
include the option of 5-ASA agents (NICE 2016).
Tumour necrosis factor-alpha (TNF-α) antagonists may provide a
benefit in post-operative Crohn’s disease (Doherty 2009; Gordon
2011), but issues of cost and safety exist (Di Sario 2016)
How the intervention might work
Corticosteroids, budesonide and 5-ASA agents all act as anti-in-
flammatory agents.
Azathioprine is a prodrug which is non-enzymatically degraded to
6-mercaptopurine which in turn is metabolised to the active com-
ponent, 6-thioguanine nucleotide (6-TGN). 6-TGN is thought to
work by inhibiting the proliferation of T and B lymphocytes and
reducing the numbers of cytotoxic T cells and plasma cells. There
are some trial data which suggest that neutrophil count is a predic-
tor of induction and maintenance of remission in Crohn’s disease
(Colonna 1994), which may suggest the mechanism of action,
although this is not well understood. The major limiting factor
for the long term use of azathioprine has been the occurrence of
adverse events leading to withdrawal of therapy in approximately
10% of patients (Hafraoui 2002), with dose-dependent and id-
iosyncratic adverse events occurring.
TNF-α antagonists are monoclonal antibodies directed towards
TNF-α. Although TNF-α antagonists have been the benchmark
biologic therapies for more than a decade, the exact mechanism
of action is still incompletely understood (Levin 2016).
The mechanism by which probiotics and antibiotics may act is
poorly understood. Due to the role that dysbiosis plays in IBD,
it has been hypothesised that there is benefit in trying to restore
the indigenous flora. Several observations, both in humans and
animal models, emphasized the importance of bacterial flora in
IBD pathogenesis, justifying the current interest in antibiotic and
probiotic therapies aimed at themanipulation of enteric flora (Cui
2004).
Why it is important to do this review
Given the impact of surgical resection on Crohn’s disease patients,
clear evidence regarding management strategies to maintain a dis-
ease free state post-surgically is vital for both patients and clini-
cians. Many researchers have argued that the state of the gut post-
surgery ismassively different from a histological and clinical stand-
point (Gordon 2017), and previous reviews have found that some
standard treatments work in this setting and some do not (Gordon
2011; Gordon 2014). With a wide range of strategies available
and no clear hierarchy regarding the efficacy of these treatments,
evidence-based decision making is currently not possible. Addi-
tionally, given the variability in adverse event profiles and tolera-
bility of the agents being considered, clarification of these issues
is needed.
Comparative efficacy and safety data are best achieved by head-to-
head trials. However, multiple trials of this sort will be needed and
attracting funding to complete these trials may be difficult and
take significant time, if these trials are conducted at all. Thus far,
there are limited active head-to-head trials comparing treatments
for maintaining post-surgical remission in Crohn’s disease. An al-
ternative strategy for obtaining comparative data is to conduct a
network meta-analysis (NMA) in which multiple treatments are
compared using both direct comparisons of interventions within
randomised controlled trials (RCTs) and indirect comparisons
across trials based on a common comparator (i.e. placebo). In
other words, if compound A is compared with compound B in
one trial, and the same compound B is compared with compound
C in another trial, indirect information can be obtained for the
comparison of compound A to compound C using this technique.
O B J E C T I V E S
To assess the effects and harms of interventions for the mainte-
nance of surgically-induced remission in Crohn’s disease and to
rank treatments in order of effectiveness.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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We will include published and unpublished RCTs irrespective of
language or year of publication. We will exclude studies which use
quasi-random methods of allocation (e.g. date of birth).
Types of participants
Trials enrolling participants of any age with Crohn’s disease as de-
fined by conventional clinical, radiological or endoscopic criteria
will be considered for inclusion.
Patients must be in remission as defined by a recognized Crohn’s
disease activity index or endoscopy following surgery on recruit-
ment, or who had undergone a surgical resection (as defined by
the authors of the primary studies) no more than six months prior
to starting maintenance treatment. We will only include studies
with a mixed population (both medically and surgically-induced
remission) provided outcome data for participants with surgically-
induced remission are reported separately.
Types of interventions
We will consider trials comparing oral or topical corticosteroids,
5-ASA agents, purine analogues, TNF-α antagonists, other classes
of biologic agents, probiotics, antibiotics or any other pharma-
ceutical intervention with no treatment, placebo or another active
treatment for inclusion. Studies where participants received con-
comitant treatments which are not routinely administered for the
purpose of maintaining remission (such as antidiarrhoeal medi-
cation, antibiotics or tapered steroids) will be included. Dose op-
timisation studies will not be included. Given the scope of over-
lapping and ongoing reviews, we will not consider trials assess-
ing enteral diet, diet manipulation, herbal medicine or nutritional
supplementation.
Types of outcome measures
Primary outcomes
The primary outcome will be clinical relapse. We will regard the
following as providing the most relevant measures of outcome for
the analyses:
• proportion of patients who fail to maintain clinical
remission, as defined by the original studies
• time to relapse (survival data: study-level data reported as a
hazard ratio (HR) with standard error (SE)).
Wewill accept the authors’ definitions of what constitutes a clinical
relapse.
Secondary outcomes
The secondary outcome measures will include the proportion of
patients who:
1) Experience endoscopic relapse, as definedby the original studies;
2) Experience histologic relapse, as defined by the original studies;
3) Experience adverse events (as defined by FDA 2018. We will
also note where studies fail to provide sufficient information and
simply report outcome as ‘adverse event’);
4) Experience serious adverse events (as defined by FDA 2018.We
will also note where studies fail to provide sufficient information
and simply report outcome as ‘serious adverse event’); and
5) Withdraw due to adverse events.
We will report outcome measures at the last time point available
(assumed to be at the end of follow-up if not specified) and the
time point specified in the methods as being of primary interest (if
this was different from the latest time point available). However,
we will also indicate when studies report outcomes at other time
points.
Search methods for identification of studies
A. Electronic searching
We will search the following electronic databases from inception
to present date, for relevant studies:
1. MEDLINE;
2. Embase;
3. CENTRAL;
4. Cochrane IBD Group Specialized Register;
5. Clinical trials.gov; and
6. The World Health Organization International Clinical Trials
Registry Platform (ICTRP).
The search strategy will not be limited by language (see Appendix
1).
B. Reference searching
The references of all identified studies and relevant systematic
reviews will be inspected for more trials.
C. Abstracts of major gastroenterology meetings
A manual search of abstracts submitted to major gastroenterology
meetings (2015 to 2018) will be performed for the following jour-
nals to identify more trials that may have not been published in
full at the time of the review:
1. Gastroenterology (American Gastroenterological Association);
2. Gut (British Society of Gastroenterology);
3. American Journal of Gastroenterology (American College of
Gastroenterology);
4. Canadian Journal of Gastroenterology (Canadian Association
of Gastroenterology);
5. Journal of Pediatric Gastroenterology and Nutrition (European
Society of Paediatric Gastroenterology, Hepatology and Nutri-
tion); and
6. Journal of Pediatric Gastroenterology and Nutrition (North
American Society of Paediatric Gastroenterology, Hepatology and
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Nutrition).
D. Personal contacts
Leaders in the fieldwill be contacted to try to identify other studies.
E. Drug companies
The manufacturers of relevant agents will be contacted for addi-
tional data.
Data collection and analysis
Selection of studies
Papers (or abstracts) that appear to be potentially relevant will be
identified by two authors. The authors, after reading the full texts,
will independently assess the eligibility of all trials identified using
the inclusion criteria above. Disagreement among authors will be
resolved by discussion and consensus. If disagreements cannot be
resolved, we will employ a third author for resolution.
Data extraction and management
A data extraction form will be developed and used to extract infor-
mation on relevant features and results of included studies. Two
authors will independently extract and record data on the prede-
fined checklist. Extracted data will include the following items:
a. Characteristics of patients: age, sex, disease distribution, disease
duration, disease activity index;
b. Total number of patients originally assigned to each treatment
group;
c. Intervention: type and dose of agent;
d. Control: placebo, other drugs;
e. Concurrent medications; and
f. Outcomes: time of assessment, length of follow up, type of
Crohn’s disease activity index used, definitions of remission and
relapse, site of surgery, relapse rates, adverse events.
Assessment of risk of bias in included studies
Two authors will independently assess bias using the Cochrane
risk of bias tool (Higgins 2011). The study features to be assessed
include:
a. Random sequence generation;
b. Allocation concealment;
c. Blinding of participants and personnel;
d. Blinding of outcome assessment;
e. Completeness of outcome data;
f. Selective reporting; and
g. Other sources of bias.
We will rate each of these factors as ‘low risk’, ‘high risk’ or ‘unclear
risk’ of bias. After risk of bias assessment has been carried out at
study level, we will then use the CINeMAweb tool to calculate the
percentage contribution of each direct contrast to each network
estimate (CINeMA 2017).
Measures of treatment effect
We will calculate the risk ratio (RR) and corresponding 95% con-
fidence interval (95% CI) for dichotomous outcomes using a ran-
dom-effects model. We will calculate the mean difference (MD)
and corresponding 95% CI for continuous outcomes measured
using the same units. We plan to calculate the standardised mean
difference (SMD) and corresponding 95%CI for continuous out-
comes where different scales were used to evaluate the same out-
come. The treatment effects will be summarized in terms of the
RR estimates and associated two-sided 95% confidence intervals
(CI).
Unit of analysis issues
Given the nature of the interventions, it is thought that only simple
parallel group design trials will have been conducted, with no
cluster randomised trials. If cluster randomised trials are identified,
these will be included and, if unit of analysis issues are identified
(e.g. randomisation and analysis at different units), the sample
sizes or standard errors will be adjusted appropriately (Higgins
2011).Where cross-over trials are identified, these will be included
and the effect estimates from the first period prior to cross-over
included in the meta-analysis. Where outcomes are reported at
several time points, analyses will be undertaken at single time point
that is consistently reported by the trials and at the longest point
of follow-up. Where network meta-analyses are conducted, the
effects of correlated effect estimates will be accounted for using
appropriate methods (see Data synthesis).
Dealing with missing data
Where dichotomous outcome data are missing, we will use an in-
tention-to-treat principle (ITT). The ITT principle will be ap-
plied on the assumption that all patients lost to follow-up were
treatment failures.
Assessment of heterogeneity
Heterogeneity and inconsistency will be assessed to ensure the
validity of the analysis. Initially heterogeneity will be assessed
through visual inspection of forest plots and the calculation of the
Chi² and I² statistics (Borenstein 2009). For the network meta-
analyses, the between study standard deviation will be used to as-
sess heterogeneity, with a threshold of 0.5 indicating heterogene-
ity. Consistency within the analysis will be assessed through com-
parison of the estimates of treatment effect for each comparison
from the direct and indirect pairwise meta-analyses for the closed
loops within the NMA, using a node splitting approach (Cooper
4Interventions for maintenance of surgically-induced remission in Crohn’s disease: a network meta-analysis (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2009; Dias 2010). It is important that the direct and indirect evi-
dence for the same comparisons agree, as joint analysis on an in-
consistent network can be misleading. Possible explanations for
heterogeneity will be examined where sufficient data are available,
including factors such as participant characteristics (e.g. age, sex),
condition severity, treatment type and dose, healthcare system, and
country. Where appropriate, these factors will be investigated fur-
ther through sub-group analyses and meta-regression (Borenstein
2009). Sensitivity analyses will explore possible causes of method-
ological heterogeneity, where sufficient data are available (Sutton
2000). This would include assessing the effects of studies that may
be affected by factors such as risk of bias associated with allocation
concealment, high loss to follow-up or lack of blinding in assess-
ment of outcomes.
Assessment of reporting biases
If there is an appropriate number of studies in a pooled analysis
(i.e. > 10 studies), we plan to investigate potential publication bias
using funnel plots (trial effects versus trial size).
Data synthesis
Studies will be synthesised through a narrative review with tabu-
lation of results of included studies. Where possible, treatment ef-
fects for all comparisons and outcomes will be synthesized through
meta-analyses, with the approach taken dependant on the out-
come assessed and the data available (Borenstein 2009). Where
the outcomes represent time-to-event data (e.g. time to relapse),
the (log) hazard ratio (HR) with 95% CI (or CrI) will be used
as the summary measure, adopting the approaches suggested by
Sutton et al. given the available data (Egger 2001; Parmar 1998;
Sutton 2000).
Different approaches will be taken for the meta-analysis. First, di-
rect comparisons of treatment effects will be conducted through
pairwise meta-analyses. Second, the opportunity for estimating a
network meta-analysis (NMA) will be assessed to compare differ-
ent interventions through both direct and indirect evidence within
connected networks of trials (Spiegelhalter 2004; Welton 2012).
The use of direct and indirect evidence can strengthen inferences
about the relative efficacy of the interventions being compared,
whether due to a lack of, or sparse, evidence comparing the differ-
ent interventions. Importantly, NMAs allow for the comparison
of multiple interventions simultaneously and for an estimation
of the rank order based on efficacy (Welton 2012). The network
for the models will be presented graphically through network di-
agrams, allowing assessment of both the structure and extent of
the evidence available for the different comparisons. As already
noted, where heterogeneity is identified its possible causes will be
investigated through the inclusion of patient and study level char-
acteristics as covariate within meta-regression analyses. The meta-
regression will include factors such as baseline risk (surrogate mea-
sure of patient characteristics) and length of follow-up (Gordon
2011; Gordon 2014), adopting the approach outlined by Achana
et al (Achana 2013). Where multiple active treatment arms of the
same class of drug or different doses of the same drug are included,
comparisons may be correlated, influencing the outcome measure.
Such correlations will be accounted for by assuming that the treat-
ment effects from multi-arm studies are from a multivariate nor-
mal distribution, decomposing it into a series of conditional uni-
variate distributions (Warren 2014). Some interventions have been
considered to be sufficiently similar to have a ‘class effect’, with
meta-analyses ‘lumping’ these interventions together. Aminosali-
cylates will be split into two separate interventions: sulfasalazine
and 5-ASA (e.g. mesalazine, mesalamine, etc.). As pooling treat-
ments that may be heterogeneous does not meet the consistency
assumption, with the potential to cause conflict between the direct
and indirect evidence, NMAs for the individual and the classes of
interventions will be estimated where evidence allows and the es-
timates compared (Welton 2012). Where interventions routinely
used for maintaining remission are administered as concomitant
treatments, such studies will be excluded from the network.
All NMAs will take a Bayesian approach through Markov Chain
Monte Carlo (MCMC) simulation. The parameters considered in
the models will be the treatment effect of an intervention com-
pared with other interventions, with the likelihood function de-
pendent on the outcome used. As the primary outcome (i.e. clin-
ical relapse) represents the number of events that occur within a
patient population allocated to a particular treatment, a binomial
distribution will be assumed for the likelihood. Trial specific log-
odds ratios (ORs) will be assumed to be from the normal distri-
bution. Different prior distributions will be used for the scale pa-
rameters (e.g. a uniform distribution for the base case and half-
normal and inverse gamma distributions for sensitivity analyses).
Vague priors will be used for the treatment effects in the different
models. All models will be estimated using three chains starting
with different initial values. Convergence will be assessed through
visual inspection of the Brooks-Gelman-Rubin diagnostic, with
convergence assumed to have occurred when the ratio of between
and within chain variability is stable around one. Varying iter-
ations and burn-in periods will be used to ensure convergence,
with burn-in periods discarded from the analysis. Autocorrelation
plots will be examined, with different rates of thinning applied to
eliminate or reduce its effects where present.
Adequacy of the fit of the models will be assessed through a com-
parison of the residual deviance for the models with the num-
ber of unconstrained data points available, with an adequate fit
when both closely match. Model selection and overall goodness of
fit will be assessed through deviance information criteria (DIC),
with a threshold of a difference of three to five points considered
significant (lowest DIC most appropriate fit) (Spiegelhalter 2002,
Welton 2012). The adequacy of the approach used for the NMA
will be assessed using a standard critical appraisal tool (Jansen
2014).
Pairwise meta-analyses of direct comparisons will be conducted
5Interventions for maintenance of surgically-induced remission in Crohn’s disease: a network meta-analysis (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
using RevMan (Version 5.3. Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2014.) and STATA v14.2
(version 14.2, StataCorp, Texas, USA) (Higgins 2011, Egger
2001), while NMAs will be estimated using the WinBUGS soft-
ware (version 1.4.3) ( MRC Biostatistics Unit, Cambridge, UK) (
http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/contents.shtml).
Subgroup analysis and investigation of heterogeneity
Assessment of statistical heterogeneity
To carry out a statistical assessment of the disagreement between
estimates within each pairwise comparison, we plan to use the I²
statistic (Higgins 2011). We will also visually assess the overlap
of the confidence intervals with the prediction interval and the
variability in the point estimates. I² thresholds will be interpreted
as follows:
• < 50% will be regarded as low;
• 50 to 75% will be regarded as moderate; and
• > 75% will be regarded as large.
Assessment of statistical inconsistency
We will also assess whether there is disagreement between direct
and indirect estimates or between indirect estimates through dif-
ferent intermediate treatments in the network. This will be done
for single loops of evidence within the network and for the net-
work as a whole (Dias 2013; Salanti 2014). Given that these tests
are often underpowered, we will carry out the assessment using
the 90% significance level.
Local approaches to evaluating inconsistency
The first stage involves separately synthesising the evidence for
each pairwise contrast. This method tests the consistency assump-
tion for each closed loop of the network separately then themagni-
tude of the inconsistency factors and their confidence intervals can
be used for making inferences about the presence of inconsistency
in each loop. We will present the results of this approach graph-
ically in a forest plot using the ’ifplot’ command in Stata 2017.
This will be followed by the node splitting approach comparing
direct and indirect relative treatment effects. For instance, a di-
rect estimate of C versus B is compared with the indirect estimate
from AB versus AC (Dias 2013). A test of the null hypothesis that
there is no inconsistency is obtained using a Z-test. One test will
be carried out for each treatment comparison. The ratio of odds
ratios with confidence interval will be calculated each time. A con-
fidence interval which excludes 1 indicates statistically significant
inconsistency.
Global approaches to evaluating inconsistency
We will carry out a global assessment of inconsistency in the net-
work using a Chi² test. This is useful in assessing whether the as-
sumption of consistency holds for the entire network. Treatment
comparisons that take ≥90% of the information from direct ev-
idence are unlikely to have concerns for inconsistency. For com-
parisons with at least 10% of information derived from indirect
evidence, a P value < 0.01, 0.01 to < 0.1 and > 0.1 will be inter-
preted as major, some and no concerns respectively
Investigation of heterogeneity and inconsistency
If sufficient studies are available, wewill perform subgroup analyses
assessing the effect of time since surgery (≤30 days versus >30
days), duration of follow-up (≤ 12 months versus > 12 months)
and type of remission (clinical versus endoscopic) on the outcomes.
Sensitivity analysis
Methodological heterogeneity will be examined through sensitiv-
ity analysis, including components of risk of bias such as allocation
concealment, loss to follow-up or blinding of outcome assessment.
Data permitting, we will also exclude studies which are outliers
in terms of dose of intervention, definition of outcome, direction
or size of treatment effect or those identified as inconsistent by
inconsistency testing.
Quality assessment of evidence generated from the
network meta-analysis (NMA)
We will assess the certainty of the evidence using GRADE
(Schünemann 2011a; Schünemann 2011b). We will apply this
methodology to the network meta-analysis by focusing on the ap-
proach of Salanti 2014. This will be carried out using GRADEpro
and the CINeMA webtool (CINeMA 2017), where possible. We
will assess evidence quality in two main ways, firstly, for each con-
trast and secondly, for the network as a whole, in order to assess
the quality of the ranking order.We will assess individual GRADE
factors as follows:
• Risk of bias: we will assess overall risk of bias for each
contrast and also for the entire network.
• Indirectness: this relates to whether the population,
intervention and outcome in the studies differ from those we
have proposed (see Criteria for considering studies for this
review) as well as intransitivity.
• Inconsistency: at the level of the contrast, we will take into
consideration both heterogeneity in the direct evidence for that
comparison and inconsistency related to different routes of
analysis for the comparison (e.g. direct versus indirect evidence
and two-arm versus three-arm trials). The latter will be
conducted using a node splitting approach (Dias 2013). As well
as assessing the meta-analyses of the direct evidence for
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inconsistency, we will consider the NMA predictive intervals for
that comparison in relation to GRADE ’default’ minimum
important differences (0.75 and 1.25) (Guyatt 2011). We note
that inconsistency can only be assessed where there is both direct
and indirect evidence. GRADE inconsistency will be assessed as
serious limitations if there is heterogeneity in the direct estimate
or inconsistency in the network with respect to that comparison.
Very serious limitations will be attributed to the comparison if
there is severe heterogeneity or severe inconsistency or limitations
with both heterogeneity and inconsistency. Judgements on the
magnitude of limitations will be determined by the reviewers
through discussions. Rationales will be described transparently in
the review report. At the level of the network, we will consider
the global Wald test for inconsistency. Tests of this nature are
typically underpowered, so a P value less than 0.1 will be
considered significant. Additionally, if several contrasts show
direct and indirect results that would have led to different
clinical decisions, we will consider inconsistency to be present.
• Imprecision: at the level of the contrast, we will assess
inconsistency for each pairwise comparison using the GRADE
default minimally important difference values of 1.25 and 0.75
for the RR. We will also take into account the sample size for the
direct evidence informing this contrast and consider it in relation
to the optimal information size. At the level of the network, we
will assess the overlap of the rankograms and the magnitude of
the surface under the cumulative ranking (SUCRA) curve
estimates.
• Publication bias: will also be assessed for each pairwise
comparison using standard GRADE; we will use contour
enhanced funnel plots where appropriate (where there are 10 or
more studies). We will use the contributions matrix to translate
these judgements to the network as a whole.
The CINeMA (Confidence in Network Meta-Analysis) webtool
assesses NMA evidence based on the five GRADE domains listed
above and downgrades pairwise, mixed and indirect evidence de-
pending on whether there are major, some or no concerns.
Summary of findings table
We plan to present the main results on clinical relapse and with-
drawal due to adverse events in ’Summary of findings’ tables, re-
porting the results for a representative set of contrasts, with one
row for each intervention versus the reference comparator. These
tables will present key information concerning the certainty of
the evidence, the magnitude of the effects of the interventions ex-
amined, and the sum of the available data (Schünemann 2011a).
’Summary of findings’ tables also include an overall grading of the
evidence using the GRADE approach.
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A P P E N D I C E S
Appendix 1. Search strategies
Embase
1. random$.mp.
2. factorial$.mp.
3. (crossover$ or cross over$ or cross-over$).mp.
4. placebo$.mp.
5. single blind.mp.
6. double blind.mp.
7. triple blind.mp.
8. (singl$ adj blind$).mp.
9. (double$ adj blind$).mp.
10. (tripl$ adj blind$).mp.
11. assign$.mp.
12. allocat$.mp.
13. crossover procedure/
14. double blind procedure/
15. single blind procedure/
16. triple blind procedure/
17. randomized controlled trial/
18. or/1-17
19. Exp Crohn disease/
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20. Crohn*.mp.
21. IBD.mp.
22. Inflammatory bowel disease*.mp.
23. or/ 19-22
24. Exp Surgery/
25. Surgical*.mp.
26. Surgical resection.mp.
27. Colectomy.mp.
28. Resection*.mp.
29. or/24-28
30. Exp Post Operation/
31. Post-operative.mp.
32. Post opera*.mp.
33. Postopera*.mp.
33. or/ 30-33
34. Exp Corticosteroids/
35. (Corticosteroid* or Budesonide or Prednisone or Prednisolone or Hydrocortisone or Methylprednisolone).mp.
36. Exp 5-ASA/
37. (5- aminosalicylic acid or 5-aminosalicylates or Aminosalicylates or Mesalamine or Mesalazine or Sulfasalazine).mp.
39. Exp Purine analogues/
40. Tumor necrosis factor inhibitor*.mp.
41. TNF-antagonist.mp.
41. (Immunomodulator* or Azathioprine or Mercaptopurine or Infliximab or Adalimumab or Certolizumab or Methotrexate or
Natalizumab or Vedolizumab or Ustekinumab).mp.
42. Exp Antibiotics/
43. (Antibiotic* or Ciprofloxacin or Metronidazole).mp.
44. (Probiotic* or Prebiotic*or Supplement* or Calcium or Acetaminophen or Ibuprofen or Fiber*).mp.
45. or/34-44
46. 18 and 23 and 29 and 33 and 45
MEDLINE
1. random$.tw.
2. factorial$.tw.
3. (crossover$ or cross over$ or cross-over$).tw.
4. placebo$.tw.
5. single blind.mp.
6. double blind.mp.
7. triple blind.mp.
8. (singl$ adj blind$).tw.
9. (double$ adj blind$).tw.
10. (tripl$ adj blind$).tw.
11. assign$.tw.
12. allocat$.tw.
13. randomized controlled trial/
14. or/1-13
15. Exp Crohn disease/
16. Crohn*.mp.
17. IBD.mp.
18. Inflammatory bowel disease*.mp.
19. or/ 15-18
20. Exp Surgery/
21. Surgical*.mp.
22. Surgical resection.mp.
23. Colectomy.mp.
10Interventions for maintenance of surgically-induced remission in Crohn’s disease: a network meta-analysis (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
24. Resection*.mp.
25. or/20-24
26. Post operation.mp.
27. Post-operative.mp.
28. Post opera*.mp.
29. Postopera*.mp.
30. or/26-29
31. Exp Corticosteroids/
32. (Corticosteroid* or Budesonide or Prednisone or Prednisolone or Hydrocortisone or Methylprednisolone).mp.
33. Exp aminosalicylic acid/
34. (5- ASA or 5-aminosalicylates or Aminosalicylates or Mesalamine or Mesalazine or Sulfasalazine).mp.
35. Purine analogues.mp.
36. Tumor necrosis factor inhibitor*.mp.
37. TNF-antagonist.mp.
38. (Immunomodulator* or Azathioprine or Mercaptopurine or Infliximab or Adalimumab or Certolizumab or Methotrexate or
Natalizumab or Vedolizumab or Ustekinumab).mp.
39. Exp Antibiotics/
40. (Antibiotic* or Ciprofloxacin or Metronidazole).mp.
41. (Probiotic* or Prebiotic*or Supplement* or Calcium or Acetaminophen or Ibuprofen or Fiber*).mp.
42. or/31-41
43. 14 and 19 and 25 and 30 and 42
Cochrane CENTRAL
#1 MeSH: [Inflammatory bowel disease] explode all trees
#2 Crohn Disease
#3 Crohn
#4 IBD
#5 #1 or #2 or #3 or #4
#6 MeSH: [Colectomy] explode all trees
#7 Surgery
#8 Surgical*
#9 Surgical resection
#10 Resection*
#11 #6 or #7 or #8 or #9 or #10
#12 Post operation
#13 Post-operative
#14 Post opera*
#15 Postopera*
#16 #12 or #13 or #14 or # 15
#17 Corticosteroid* or Budesonide or Prednisone or Prednisolone or Hydrocortisone or Methylprednisolone
#18 5- ASA or 5-aminosalicylates or Aminosalicylates or Mesalamine or Mesalazine or Sulfasalazine or Aminosalicylic acid
#19 Purine Analogues
#20 Tumor Necrosis Factor-alpha
#21 Tumor necrosis factor inhibitor*
#22 Immunomodulator* or Azathioprine or Mercaptopurine or Infliximab or Adalimumab or Certolizumab or Methotrexate or
Natalizumab or Vedolizumab or Ustekinumab
#23 MeSH: [Anti-Bacterial Agents] explode all trees
#24 Antibiotic* or Ciprofloxacin or Metronidazole
#25 MeSH: [Probiotics] explode all trees
#26 Probiotic* or Prebiotic*or Supplement* or Calcium or Acetaminophen or Ibuprofen or Fiber*
#27 #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26
#28 #5 and #11 and #16 and #27
Clinicaltrials.gov/ ICTRP
1. Inflammatory bowel disease and surgery
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2. Crohn’s disease and surgery
3. Inflammatory bowel disease and resection
4. Crohn’s disease and resection
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